Text and Data Mining valid from 2020-03-04
Received: 12 October 2018
Accepted: 20 February 2020
First Online: 4 March 2020
Ethics approval and consent to participate
: Presentation of this case report followed the standard ethical procedures of the University of Colorado. Informed consent was obtained from the patient for publication of this case report and any accompanying images.
: The patient gave verbal and written consent to publish this case report, and read the article and confirmed its content.
: AD, DTM, GB and JK have no competing interests. RCD has the following interests:Advisory Board: Ignyta, Ariad/Takeda, Spectrum Pharmaceuticals, AstraZeneca.Sponsored Research Agreement: Ignyta, Loxo.Honorarium: Guardant Health.Stock ownership: Rain Therapeutics.Licensed Patents: Abbott Molecular, Rain Therapeutics.Licensed Products: Ariad, Ignyta.